TMCnet News
Molecular Partners to Present at the 33rd Annual J.P. Morgan Healthcare ConferenceMolecular Partners AG [SIX:MOLN] today announced that its CEO, Dr. Christian Zahnd, will present at the 33rd Annual J.P. Morgan Healthcare Conference on Wednesday 14 January 2015 at 3:30 PM Pacific Standard Time (6:30 PM Eastern Time). The presentation will be webcast live and can be accessed on the day via this link. A replay of the webcast will be available on the company's website: www.molecularpartners.com, within the Investors section and will be available for 30 days following the conference. About Molecular Partners AG Molecular Partners is a biopharmaceutical company that is developing a new powerful class of therapies known as DARPins™. DARPins™ are potent, specific and versatile small protein therapies, which have the potential to offer benefits over conventional monoclonal antibodies or other currently available protein therapeutics. Molecular Partners has four compounds in various stages of clinical and preclinical development and several more in research, with a current focus on ophthalmology and oncology. Abicipar, the company's lead product is expected to enter Phase III clinical trials in wet AMD (News - Alert) with partner Allergan later this year. Molecular Partners has significant partnerships with pharmaceutical companies including Allergan, Roche and Janssen. For more information about the company, please visit: www.molecularpartners.com Notes: Molecular Partners raised CHF104.1 million (US$106.1 million) in November 2014 noted as Europe's second largest biotech IPO of the year and the first biotech IPO in Switzerland in five years. For further details, please contact:
Dr. Christian Zahnd, CEO
Andreas Emmenegger, CFO
|
